Company profile
CuroNZ company profile
Curonz is a clinical stage biotechnology company with a drug portfolio covering the peptide family, Neural Regeneration Peptides (NRPs), which were discovered by Curonz's founding Director, Dr Frank Sieg and where precursor compounds to our clinical molecule NRP2945 were first patented back in 2001. We currently have offices in Delaware, NZ and Australia. We have completed Clinical Phase I in Australia for our lead drug candidate NRP2945 with 49 healthy volunteers. Currently, we are studing NRP2945 in a small Phase II proof of concept study in adults with typical absence epilepsy which is due to finish mid 2019. We are..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Website
- http://curonz.com/
- Contact email
- [email protected]
- Phone number
- 64 21 500 453
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00001-00010 employees
- Founded
- 2010-01-01
Headquarters
- Headquarters
- Wellsford, Auckland, New Zealand
- Postal code
- 0975
- Country code
- NZ
- Continent
- Oceania